Haifaa Abdulhaq, MD

Title(s)Professor, Medicine - Fresno
SchoolSchool of Medicine
AddressUCSF Fresno Dept Medicine
155 N Fresno Street
Fresno CA 93701
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Haifaa Abdulhaq, M.D.
    Clinical Professor, UCSF

    Haifaa Abdulhaq, M.D. is Clinical Professor in Hematology and Oncology, UCSF and she is the director of hematology at UCSF Fresno and the director of Hematology/Oncology fellowship program at UCSF Fresno. She is board certified in hematology and medical oncology with expertise in Malignant Hematology including Lymphoproliferative neoplasms, Myeloproliferative neoplasms, Acute Leukemia, Multiple Myeloma and interest in Stem Cell transplantation.

    Dr. Abdulhaq completed her residency in internal medicine and fellowship in hematology & oncology at Western Pennsylvania Hospital and Allegheny General Hospital in Pittsburgh, Pennsylvania.

    She is a member of The American Society of Hematology, the American Board of Internal Medicine, the American Society of Clinical Oncology and the American Society of Blood and Bone Marrow Transplantation. Dr. Abdulhaq is a board member of the Leukemia and Lymphoma Society, Central California Chapter and she also serves as the chair of Cancer Committee at Community Medical Centers.

    Dr. Abdulhaq has special interest in medical education. She is a recipient of Henry Kaiser Award for Excellence in teaching at UCSF . She is also interested in clinical research and serves as the principal investigator on many clinical trials in malignant hematology.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024 Nov 16; 404(10466):1940-1954. Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP. PMID: 39550172.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    2. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer J. 2024 Aug 12; 14(1):134. Pawlyn C, Schjesvold FH, Cairns DA, Wei LJ, Davies F, Nadeem O, Abdulhaq H, Mateos MV, Laubach J, Weisel K, Ludwig H, Rajkumar SV, Sonneveld P, Jackson G, Morgan G, Richardson PG. PMID: 39134544; PMCID: PMC11319634.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. Morvan Fibrillary Chorea Associated with Monoclonal B Cell Lymphocytosis. Am J Case Rep. 2024 Jul 04; 25:e943867. Park D, Means J, Campion AW, Kelton A, Nagpal S, Abdulhaq H. PMID: 38963810; PMCID: PMC11322787.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    4. Optimizing Acute Sickle Cell Care at Community Health Partners Medical Center. Blood. 2023 Nov 28; 142(Supplement 1):7234. Means MJ, Palmer PN, Uller UJ, Park PD, Hwang HA, Chinnock CB, Treadwell TM, Macmillan MP, Abdulhaq AH, Viau VW, Ravi RN, Bukari BS. .
      View in: Publisher Site   Mentions:
    5. Trends in Diffuse Large B-Cell Lymphoma Mortality in the United States: A Comprehensive Review from 2000 to 2020. Blood. 2023 Nov 28; 142(Supplement 1):1765. Armashi AA, Zubaidi ZA, Mahmood MO, Thierheimer TM, Alkrekshi AA, Abdulhaq AH. .
      View in: Publisher Site   Mentions:
    6. Realmind: A Prospective and Retrospective Study to Characterize Real-World Use of Tafasitamab Plus Lenalidomide in US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, with a Focus on Patients from Minority Groups. Blood. 2023 Nov 28; 142(Supplement 1):6251. Brem BE, Burke BJ, Vukcevic VM, Kloepfer KP, Saverno SK, Abdulhaq AH, Evens EA, Porcu PP, Shadman SM, Flowers FC. .
      View in: Publisher Site   Mentions:
    7. Disparities in Genetic Profiles, Risk Stratification and Outcomes in Adults with Acute Myeloid Leukemia Comparing Patients of Hispanic and Non-Hispanic Ethnicity in Central California. Blood. 2023 Nov 28; 142(Supplement 1):7423. Mahmood MO, Saini ST, Park PD, Bekal BS, Bal BI, Saini SS, Altai AT, Fayed FY, Yan YY, Abdulhaq AH. .
      View in: Publisher Site   Mentions:
    8. Trial in Progress: A Phase I/II Study of Tafasitamab Plus Lenalidomide in Patients with Relapsed CNS Lymphoma. Blood. 2023 Nov 28; 142(Supplement 1):3104. Randall RM, Rauschecker RA, Gima-Lange GL, Wilmoth WJ, Chen CL, Lu LM, Geng GH, Abdulhaq AH, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    9. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study. Eur J Haematol. 2024 Mar; 112(3):402-411. Schjesvold FH, Ludwig H, Mateos MV, Larocca A, Abdulhaq H, Norin S, Thuresson M, Bakker NA, Richardson PG, Sonneveld P. PMID: 37968873.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context. Onco Targets Ther. 2023; 16:617-629. Abdulhaq H, Hwang A, Mahmood O. PMID: 37492075; PMCID: PMC10364833.
      View in: PubMed   Mentions: 1  
    11. Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2023 10; 23(10):749-756. Othman T, Quan MA, Zhang S, Gaut D, Young PA, Mahmood O, Abdulhaq H, Shieh K, Reid J, Brem EA, Hariharan N, Heyman B, Tuscano J. PMID: 37336714.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies. Clin Lymphoma Myeloma Leuk. 2023 09; 23(9):687-696. Sonneveld P, Richardson PG, Ludwig H, Dimopoulos MA, Schjesvold FH, Hájek R, Abdulhaq H, Thuresson M, Norin S, Bakker NA, Mateos MV. PMID: 37355418.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity. 2022; 140(supplement):3553-3554. Haifaa Abdulhaq, Omar Mahmood, Calvin Kuan Jung Chen, Azra Borogovac, Matthew Wieduwilt, Anand Annan, Yueqi Yan, Maher Albitar. View Publication.
    14. Avoiding Daratumumab Interference with Blood Typing. Blood. 2022 Nov 15; 140(Supplement 1):13076-13077. Huang HC, Boulbol BF, Bekal BS, Policepatil PS, Abdulhaq AH, Bukari BS. .
      View in: Publisher Site   Mentions:
    15. OCEAN (OP-103): Melflufen/Dexamethasone Compared Wth Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - Subgroup Analysis in Patients Refractory to Prior Alkylators. Blood. 2022 Nov 15; 140(Supplement 1):12607-12609. Schjesvold SF, Ludwig LH, Mateos MM, Abdulhaq AH, Norin NS, Thuresson TM, Bakker BN, Richardson RP, Sonneveld SP. .
      View in: Publisher Site   Mentions:
    16. Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Blood. 2022 Nov 15; 140(Supplement 1):4851-4852. Othman OT, Quan QM, Zhang ZS, Gaut GD, Young YP, Abdulhaq AH, Shieh SK, Reid RJ, Brem BE, Heyman HB, Tuscano TJ. .
      View in: Publisher Site   Mentions:
    17. Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity. Blood. 2022 Nov 15; 140(Supplement 1):3553-3554. Abdulhaq AH, Mahmood MO, Chen CC, Borogovac BA, Wieduwilt WM, Annan AA, Yan YY, Albitar AM. .
      View in: Publisher Site   Mentions:
    18. A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma. Blood. 2022 Nov 15; 140(Supplement 1):11954-11955. Othman OT, Rosenberg RA, Timmerman TJ, Heyman HB, Abdulhaq AH, Tuscano TJ. .
      View in: Publisher Site   Mentions:
    19. Characteristics and Outcomes of Multiple Myeloma in Hispanic Versus Non-Hispanic Patients in Central California. Blood. 2022 Nov 15; 140(Supplement 1):12568-12569. Hwang HA, Park PD, Doornenbal DJ, Bal BI, Bukari BS, Yan YY, Abdulhaq AH. .
      View in: Publisher Site   Mentions:
    20. Poster: ABCL-051 realMIND: A Prospective, Multicenter, Observational Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second/Third-Line Therapy and Not Receiving a Stem Cell Transplant. Clinical Lymphoma Myeloma & Leukemia. 2022 Oct 1; 22:s171. Flowers FC, Burke BJ, Vukcevic VM, Snodgrass SS, Saverno SK, Lumiqued LM, Abdulhaq AH, Brem BE, Evens EA, Farooq FU, Porcu PP, Shadman SM. .
      View in: Publisher Site   Mentions:
    21. ABCL-051 realMIND: A Prospective, Multicenter, Observational Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second/Third-Line Therapy and Not Receiving a Stem Cell Transplant. Clinical Lymphoma Myeloma & Leukemia. 2022 Oct 1; 22:s355-s356. Flowers FC, Burke BJ, Vukcevic VM, Snodgrass SS, Saverno SK, Lumiqued LM, Abdulhaq AH, Brem BE, Evens EA, Farooq FU, Porcu PP, Shadman SM. .
      View in: Publisher Site   Mentions:
    22. Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin. Leuk Lymphoma. 2022 12; 63(12):3008-3011. Guan T, Lo M, Young R, Ai W, Boulbol F, Mouanoutoua H, Chu R, Andreadis C, Kaplan L, Abdulhaq H, Fakhri B. PMID: 35875857.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2022 10; 22(10):e947-e957. Othman T, Penaloza J, Zhang S, Daniel CE, Gaut D, Oliai C, Brem EA, Baweja A, Ly J, Reid J, Pinter-Brown L, Lee M, Abdulhaq H, Tuscano J. PMID: 35858904.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    24. Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature. Case Rep Hematol. 2022; 2022:8331766. Lee M, Martin BA, Abdulhaq H. PMID: 35795542; PMCID: PMC9252825.
      View in: PubMed   Mentions: 1  
    25. Clinicopathological characteristics of high-risk multiple myeloma in Hispanic versus non-Hispanic patients in central California. Journal of Clinical Oncology. 2022; 40(16-suppl). Andrew Hwang, Jason Doornenbal, Daniel Park, Inderpreet Bal, Mohammed SANI Bukari, Yueqi Yan, Haifaa Abdulhaq. . View Publication.
    26. Clinicopathological characteristics of high-risk multiple myeloma in Hispanic versus non-Hispanic patients in central California. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):8056-8056. Hwang HA, Doornenbal DJ, Park PD, Bal BI, Bukari BM, Yan YY, Abdulhaq AH. .
      View in: Publisher Site   Mentions:
    27. Ethnic Variation in Hospitalized COVID-19 Patients and Correlation with Coagulopathy, Thrombosis, Prognosis and 30 Day Mortality Outcomes in California's Central Valley. Blood. 2021 Nov 5; 138(Supplement 1):4074-4074. Huang HC, Mahmood MO, Mills MP, Amini AM, Bekal BS, Doornenbal DJ, Bukari BS, Abejie AY, Abdulhaq AH. .
      View in: Publisher Site   Mentions:
    28. First-Line Treatment with R-CHOP Vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Blood. 2021 Nov 5; 138(Supplement 1):2509-2509. Othman OT, Penaloza PJ, Brem BE, Pinter-Brown PL, Baweja BA, Lee LM, Ly LJ, Reid RJ, Abdulhaq AH, Gaut GD, Oliai OC, Reid RE, Tuscano TJ. .
      View in: Publisher Site   Mentions:
    29. Clinicopathologic Characteristic and Natural History of Patients with Non Hereditary, Non Polycythemia Vera (NH/NPV) Persistent Polycythemia. Blood. 2021 Nov 5; 138(Supplement 1):4617-4617. Mahmood MO, Mouanoutoua MH, Saini ST, Okura OM, Noori NM, Almasri AN, Abdulhaq AH, Bukari BS. .
      View in: Publisher Site   Mentions:
    30. OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses. Blood. 2021 Nov 5; 138(Supplement 1):2732-2732. Richardson RP, Schjesvold SF, Abdulhaq AH, Coriu CD, Lazzaro LA, Sonneveld SP, Kullenburg KT, Harmenberg HJ, Thuresson TM, Byrne BC, Mateos MM. .
      View in: Publisher Site   Mentions:
    31. Evaluation of Pulmonary Toxicities in Lymphoma Patients Receiving Brentuximab Vedotin. Blood. 2021 Nov 5; 138(Supplement 1):2511-2511. Guan GT, Lo LM, Young YR, Boulbol BF, Mouanoutoua MH, Chu CR, Ai AW, Abdulhaq AH, Fakhri FB. .
      View in: Publisher Site   Mentions:
    32. Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients. Cancer Treat Res Commun. 2021; 27:100310. Barakat M, Albitar M, Whitney R, Abdulhaq H. PMID: 33581493.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    33. Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review. Case Rep Hematol. 2020; 2020:8823877. Valliani S, Ali M, Mahmoo O, Hinduja S, Chen CK, Damon L, Abdulhaq H. PMID: 33425404; PMCID: PMC7781713.
      View in: PubMed   Mentions: 4  
    34. Using Targeted RNA Next Generation Sequencing and Differential Expression to Compare Primary Central Nervous System Lymphoma with CD+ DLBCL, Nodal DLBCL and EBV+ DLBCL. Blood. 2020 Nov 5; 136(Supplement 1):22-22. Abdulhaq AH, Albitar AM. .
      View in: Publisher Site   Mentions:
    35. Clinicopathological Features of Double-Hit and Double-Expressor Lymphomas in Hispanics Versus Non-Hispanics in Central California. 2020; 20:S262-S263. MatthewLee, TannerMortenson, MahboubNoori, DianaMoers, Mohammed Bukari, HaifaaAbdulhaq. . View Publication.
    36. ABCL-078: Clinicopathological Features of Double-Hit and Double-Expressor Lymphomas in Hispanics Versus Non-Hispanics in Central California. Clinical Lymphoma Myeloma & Leukemia. 2020 Sep 1; 20:s262-s263. Lee LM, Mortenson MT, Noori NM, Moers MD, Bukari BM, Abdulhaq AH. .
      View in: Publisher Site   Mentions:
    37. ABCL-407: Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Sirolimus-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: A Case Report. Clinical Lymphoma Myeloma & Leukemia. 2020 Sep 1; 20:s275. Lee LM, Martin MB, Abdulhaq AH. .
      View in: Publisher Site   Mentions:
    38. Positive Response to Fluorouracil and Oxaliplatin in Signet Ring Cell Adenocarcinoma of the Bladder Presenting With Retroperitoneal Fibrosis. Cureus. 2020 Jul 21; 12(7):e9322. Hinduja S, Abdulhaq H, Valliani S, Ali MM. PMID: 32850200; PMCID: PMC7444851.
      View in: PubMed   Mentions: 1  
    39. Clinicopathologic and molecular profile of Philadelphia like ALL in Hispanic population of Central Valley California. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):7524-7524. Akabane AH, Ali AM, Abdulhaq AH, Bukari BM. .
      View in: Publisher Site   Mentions:
    40. Clinicopathologic profile of extramedullary plasmacytoma in Central Valley. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):e20551-e20551. Valliani VS, Barakat BM, Gill GH, Okudo OJ, Abdulhaq AH, Bukari BM. .
      View in: Publisher Site   Mentions:
    41. Leukemic infiltration in the settings of acute respiratory failure. Oxf Med Case Reports. 2019 Nov; 2019(11):482-485. Fayed M, Evans T, Abdulhaq H. PMID: 31844533; PMCID: PMC6902626.
      View in: PubMed   Mentions: 3  
    42. Molecular profiling of primary central nervous system lymphoma as compared to activated B-cell subtype of diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2019 May 20; 37(15_suppl):7549-7549. Barakat BM, Albitar AM, Xu-Monette XZ, Young YK, Abdulhaq AH. .
      View in: Publisher Site   Mentions:
    43. Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic population. Journal of Clinical Oncology. 2019 May 20; 37(15_suppl):7535-7535. Barakat BM, Albitar AM, Whitney WR, Chen CC, Kuo KY, Silveira SW, Bukari BM, Arekapudi AS, Dhaliwal-Binning DK, Abdulhaq AH. .
      View in: Publisher Site   Mentions:
    44. Potential of Germline CDKN2A I49T as a Targetable Driver Mutation: Prolonged Control of Refractory Osteosarcoma with CDK4/6 Inhibitor in a Familial Cancer. Journal of Carcinogenesis & Mutagenesis. 2019 Jan 1; 10(1). Tehrani TO, Abdulhaq AH, Delozier DC. .
      View in: Publisher Site   Mentions:
    45. Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant. Case Rep Hematol. 2018; 2018:6092646. Rahmat LT, Nguyen A, Abdulhaq H, Prakash S, Logan AC, Mannis GN. PMID: 30225152; PMCID: PMC6129347.
      View in: PubMed   Mentions: 20  
    46. A rare case of rosai-dorfman disease in an adult male associated with auto-immune hemolytic anemia. Mediterr J Hematol Infect Dis. 2013; 5(1):e2013022. Sachdeva M, Abdulhaq H. PMID: 23667720; PMCID: PMC3647709.
      View in: PubMed   Mentions: 6  
    47. Zosteriform Rash as the First Sign of Metastatic Non-small Cell Carcinoma of the Lung (A Case Report. CHEST Journal. 2011 Oct 1; 140(4):59a-59b. Tabassomi TM, Abdulhaq AH, Almasri AE, Hashemi HN. .
      View in: Publisher Site   Mentions:
    48. Viability and potency of hematopoietic progenitor cells after prolonged cryopreservation at -80°C. Acta Haematol. 2011; 126(2):99-102. Costa R, Khattab M, Gilmore GL, Sahovic EA, Miller SM, Rossetti JM, Abdulhaq H, Lister J. PMID: 21576935.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    49. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 2011 Jun 15; 117(12):2690-6. Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati M, Atem FD, Rossetti JM, Sahovic EA, Lister J. PMID: 21656746.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    50. Viability And Potency Of Hematopoietic Progenitor Cells After Prolonged Cryopreservation At -80 °C. Biology of Blood and Marrow Transplantation. 2010 Feb 1; 16(2):s167. Khattab KM, Gilmore GG, Sahovic SE, Miller MS, Rossetti RJ, Abdulhaq AH, Lister LJ. .
      View in: Publisher Site   Mentions:
    51. Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia. Blood. 2009 Nov 20; 114(22):4164-4164. Benjamin BH, Rossetti RJ, Lampkin LA, Hilton HC, Sahovic SE, Abdulhaq AH, Shadduck SR, Vemulapalli VN, Hercules HA, Lister LJ. .
      View in: Publisher Site   Mentions:
    52. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer. Am J Clin Oncol. 2008 Dec; 31(6):595-605. Abdulhaq H, Geyer C. PMID: 19060594.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    53. Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia. Blood. 2008 Nov 16; 112(11):4041-4041. Labban LG, Rossetti RJ, Shadduck SR, Sahovic SE, Abdulhaq AH, Goy GJ, Wilt WL, Wonder WR, Lister LJ. .
      View in: Publisher Site   Mentions:
    54. Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML). Blood. 2008 Nov 16; 112(11):5072-5072. Abdulhaq AH, Haq HB, Rossetti RJ, Shadduck SR, Sahovic SE, Christianson CD, Lister LJ. .
      View in: Publisher Site   Mentions:
    55. The role of azacitidine in the treatment of myelodysplastic syndromes. Expert Opin Investig Drugs. 2007 Dec; 16(12):1967-75. Abdulhaq H, Rossetti JM. PMID: 18042004.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    56. Erythroid variant of chronic myelogenous leukemia. Leukemia. 2008 Apr; 22(4):867-70. Talreja N, Abdulhaq H, Shadduck RK, Rossetti J, Jalil A, Makary A, Lister J. PMID: 18033324.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    57. Recent advances in myelodysplastic syndromes. Exp Hematol. 2007 Apr; 35(4 Suppl 1):137-43. Shadduck RK, Latsko JM, Rossetti JM, Haq B, Abdulhaq H. PMID: 17379099.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    58. Response to azacitidine (AZA) in patients with secondary myelodysplastic syndrome. Journal of Clinical Oncology. 2006 Jun 20; 24(18_suppl):6578-6578. Abdulhaq AH, Haq HB, Rossetti RJ, Lister LJ, Shadduck SR. .
      View in: Publisher Site   Mentions:
    Haifaa's Networks
    Concepts (86)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (17)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.